DelveInsight’s “Dry Age-Related Macular Degeneration (Dry-AMD) – Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies developing over 80 pipeline drugs in the Dry Age-Related Macular Degeneration pipeline landscape. It covers the Dry-AMD pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Dry Age-Related Macular Degeneration treatment landscape. Learn more about the evolving Dry-AMD pipeline today @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report

• On April 13, 2026, Sylentis, S.A. announced a clinical trial to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops in patients with macular degeneration.

• In January 2026, Ocugen reported that its modifier gene therapy OCU-410 slowed the growth of atrophic lesions (areas of cell death) by 46% in a Phase 1/2 clinical trial.

• Topline data from the global Phase III ReNEW trial evaluating daily subcutaneous dosing of elamipretide to slow photoreceptor loss in dry AMD are expected in 2026.

• Pivotal Phase 3 trials—ATMOSPHERE and ASCENT—for Surabgene Lomparvovec (ABBV-RGX-314), an investigational one-time gene therapy, are currently ongoing with topline data expected in 2026.

• Preliminary data from the Phase 1/2 BIRD-1 trial for OPGx-BEST1, a gene therapy for Best vitelliform macular dystrophy with implications for dry AMD research, are expected during the first quarter of 2026.

• Dry Age-Related Macular Degeneration is a leading cause of irreversible blindness, affecting approximately 170 million people globally, with geographic atrophy representing its advanced stage.

• In 2023, the United States accounted for the highest prevalent cases of dry AMD among the 7MM, with around 21 million cases expected to increase by 2034.

• DelveInsight’s Dry-AMD Pipeline Insight report depicts a robust clinical development space with 70+ active players advancing over 80 pipeline therapies across multiple stages.

• The leading Dry Age-Related Macular Degeneration companies include Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus Pharmaceuticals, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Roche, and others.

Download for updates and the latest revolution in Dry-AMD care @ Dry Age-Related Macular Degeneration Market Insight, Epidemiology And Market Forecast

Dry Age-Related Macular Degeneration Emerging Drugs Profile

Tinlarebant (LBS-008): Belite Bio

Tinlarebant is a novel oral therapy being independently developed by Belite Bio for the treatment of dry Age-Related Macular Degeneration and Stargardt disease. It is designed to reduce the accumulation of toxins in the eye that lead to retinal degeneration. Currently, Tinlarebant is in Phase III clinical evaluation, representing one of the most advanced oral candidates in the Dry-AMD pipeline.

Elamipretide: Stealth BioTherapeutics

Elamipretide is a potential first-in-class mitochondrial stabilizing agent currently being evaluated in late-stage development. It is the only class of therapy to have demonstrated a potential to improve low luminance visual acuity (LLVA) in dry AMD patients. Currently, elamipretide is the subject of the global Phase III ReNEW trial, evaluating daily subcutaneous dosing to slow photoreceptor loss, with topline data expected in 2026.

OCU-410: Ocugen

OCU-410 is a modifier gene therapy designed to slow the progression of atrophic lesions associated with geographic atrophy secondary to dry AMD. It is administered via a single sub-retinal injection and targets multiple pathological pathways, including lipid metabolism, inflammation, oxidative stress, and complement activation. Currently, OCU-410 is in Phase 1/2 clinical trial evaluation, with recent interim data showing a significant 46% reduction in lesion growth.

For more information on the Dry Age-Related Macular Degeneration Emerging Drugs Profile, download DelveInsight’s comprehensive Dry Age-Related Macular Degeneration Pipeline Insight report.

The Dry Age-Related Macular Degeneration Pipeline Report Provides

• Detailed insights about companies developing therapies for Dry Age-Related Macular Degeneration, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Dry-AMD treatment.

• Dry-AMD companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Dry-AMD drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Dry-AMD market.

Learn more about Dry Age-Related Macular Degeneration drug opportunities in our comprehensive Dry-AMD pipeline report @ Dry Age-Related Macular Degeneration Unmet Needs

Dry Age-Related Macular Degeneration Companies and Competitive Landscape

There are 70+ key companies, including Belite Bio, Alkeus Pharmaceuticals, Stealth BioTherapeutics, Ocugen, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Roche, and Novartis, developing therapies for Dry Age-Related Macular Degeneration. Multiple candidates are advancing through late-stage Phase III trials, reflecting a significant change in the upcoming forecast period.

DelveInsight’s Dry Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Dry Age-Related Macular Degeneration products have been categorized under various Molecule types such as:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Discover the latest advancements in Dry Age-Related Macular Degeneration treatment by visiting our website. Stay informed @ Dry Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspectives

Scope of the Dry Age-Related Macular Degeneration Pipeline Report

• Coverage: Global

• Dry Age-Related Macular Degeneration Companies: Belite Bio, Alkeus Pharmaceuticals, Stealth BioTherapeutics, Ocugen, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Roche, and others.

• Dry Age-Related Macular Degeneration Therapies: Tinlarebant (LBS-008), Gildeuretinol (ALK-001), Elamipretide, OCU-410, and other pipeline candidates.

• Dry Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.

• Dry Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Table of Contents

1. Introduction

2. Executive Summary

3. Dry Age-Related Macular Degeneration: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Dry Age-Related Macular Degeneration – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Dry Age-Related Macular Degeneration Key Companies

13. Dry Age-Related Macular Degeneration Key Products

14. Dry Age-Related Macular Degeneration Unmet Needs

15. Dry Age-Related Macular Degeneration Market Drivers and Barriers

16. Dry Age-Related Macular Degeneration Future Perspectives and Conclusion

17. Dry Age-Related Macular Degeneration Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services